other material
confidence high
sentiment positive
materiality 0.75
Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML
Cullinan Therapeutics, Inc.
- Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).
- Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.
- Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.
- Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8.